Trial Profile

Glybera Registry, Long-term Safety and Efficacy Follow-up in Lipoprotein Lipase Deficient (LPLD) Patients Treated With Alipogene Tiparvovec (GLYBERA)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alipogene tiparvovec (Primary)
Indications Hyperlipoproteinaemia type I
Focus Adverse reactions
Acronyms GENIALL
Sponsors uniQure

Most Recent Events

23 Nov 2023 Status changed from active, no longer recruiting to completed.
06 Jan 2020 Planned End Date changed from 1 Jun 2029 to 1 Oct 2033.
06 Jan 2020 Planned primary completion date changed from 1 Feb 2029 to 1 Sep 2033.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com